Cancer remains one of the world’s biggest killers. Lung cancer alone is responsible for 1.7 miliion deaths globally every year, and prevalence in developing markets is very much on the rise. Irrespective of geography, most cases are identified when they are already at a late stage, and the chances of beating the cancer are much slimmer.

Oncimmune’s EarlyCDT Lung blood test, first patented nearly 20 years ago, is clinically proven to detect lung cancer on average 4 years before a standard clinical diagnosis. It is a simple, non-invasive finger prick test that has been shown to save lives, as depicted in their moving “Extra Time” campaign on www.extratime.gallery.

My guest in this episode is Adam Hill, CEO of Oncimmune, who took the helm in 2018 and led the company into its current strong position, with global partnerships in place and a number of other cancer testing products soon to be announced. This is a relatively rare example of a biotech business with a product that is already saving lives.

Adam talks about the significant shift in the oncology community in recent years, to recognise the importance of the immune system in policing cancerous cells. Oncimmune’s ImmunoINSIGHTS platform supports pharma companies by working to predict immune related adverse events in patients by profiling autoantibodies and predicting the immune response. They use advanced data science to stratify or triage patients, enhancing drug development and allowing a more personalised and effective treatment.

So please listen in to this eye-opening conversation, and contact Oncimmune via the website at www.oncimmune.com - particularly If you are a clinician or a patient wanting to find out more about Oncimmune’s Early CDT test, or a pharma company and would like to know more about how Oncimmune’s ImmunoINSIGHTS platform can support your drug development.

Adam’s BIo

Adam is a dual-qualified Clinician and Mechanical Engineer with a career built at the interface of industry, academia and health systems. Over the last 2 decades he has trained in surgery in the British Army; founded a successful applied research centre at Imperial College London; provided growth strategy and investment advice to global life science companies on behalf of the British Government; led the global medical function of a multinational, publicly-listed health IT company; and pivoted a Formula One team into a developer of health technology. Currently, Adam is a Visiting Professor in Global Health Innovation at Imperial College London, sits on the Value Creation Committee of Imperial College Health Partners and is Non-Executive Director of Myrecovery.ai.

Adam graduated from Imperial College London as a Medical Doctor whilst also earning a PhD in Engineering, attending Imperial College Business School and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers.

.